Progyny (PGNY) Stock Trades Near Fair Value While Broader Checks Hint Discount

Progyny stock has delivered strong 1 year gains but the share price is still down sharply over 5 years, which makes the current valuation an important question for investors. The recent share price around US$25.94 now sits against a mixed performance record and a set of checks that lean toward the stock looking cheap on several measures.

• Over 5 years the share price has declined about 55.5%, which means long term holders have seen a large drawdown that may not fully reflect the underlying business today.
• Progyny’s ability to grow revenue efficiently from its fertility benefits platform can support the valuation, while any slowdown in employer client wins or pressure on healthcare benefit budgets may limit how much investors are willing to pay for the stock.
• The broader checks lean cheap, with Progyny scoring 5 out of 6 on value. This suggests the share price does not fully reflect what these measures imply.

The issue now is whether Progyny’s current market price already reflects its long term prospects or if the recent history of weak multi year returns has left room for upside in the valuation.

Scan other potential rebound stories with 47 high quality undervalued stocks that share Progyny’s blend of recent pressure and stronger value checks.

Does Progyny Look Fairly Valued on Earnings?

The P/E ratio is a useful reference point for Progyny because it directly links what you pay today to the earnings the company generates. At a P/E of about 25.3x, Progyny trades very close to the broader Healthcare sector average of roughly 25.0x. That suggests the market is valuing each dollar of Progyny’s earnings in line with the sector overall rather than applying a steep premium or discount.

The model driven fair P/E ratio for Progyny sits slightly higher at around 27.8x. This fair ratio reflects assumptions about the company’s growth profile, margins, size and risk compared with healthcare peers. The current P/E sits a little below that level. This indicates the stock does not screen as clearly cheap or expensive on earnings and instead clusters around what the model views as a reasonable range.

On the P/E multiple, Progyny looks priced roughly in line with what the model suggests is a fair earnings valuation.

See what the numbers say about this price — find out in our valuation breakdown.

The Progyny Narrative: What Would Justify Today's Price?

Progyny Narratives on Simply Wall St pick up where the valuation puzzle leaves off. They spell out which assumptions about Progyny’s future growth, margins and earnings would need to hold for the stock to be worth materially more or materially less than today’s price, and sit on the company’s Community page. Each narrative presents that fair value as a thesis about Progyny’s business that you can watch over time rather than treating it as a one off snapshot.

One of the top community narratives on Progyny: 23% undervalued

"Positive momentum in client retention and upselling, with renewals featuring either sustained or expanded benefits even in a cautious macro environment, enhances revenue predictability and underpins steady earnings growth..."

Read one of the top narratives on Progyny

Do you think there's more to the story for Progyny? Head over to our Community to see what others are saying!

The Bottom Line

Progyny now looks roughly fairly valued on earnings since the current P/E is close to the broader healthcare average and only slightly below the model’s fair ratio. The stronger set of value checks tilts the story toward the stock not being priced for aggressive expectations, but also not plainly mispriced. What matters most from here is whether Progyny can keep converting its fertility benefits platform into consistent revenue and profit growth that justifies at least this sector level multiple rather than seeing the market fade its expectations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com